Conversations: What can be done to generate more innovations from public-private partnerships?

Generating Innovations From Public-Private Partnerships

08.01.13 | By

Biomedical research is behind the scientific advances that have helped increase the childhood cancer survivor rate and improve and lengthen the lives of people living with HIV/AIDs, heart disease and cancer. The next set of health care challenges to overcome include dementia and Alzheimer’s disease – neurological disorders that are on the rise and will have a major impact on our communities in the next 50 years. Researchers are already at work trying to find cures or better ways to care for individuals with these conditions.

More and more, such research is being carried out using public-private partnerships – biopharmaceutical companies working with government researchers. Research from the Tufts University Center for the Study of Drug Development found that these partnerships benefit both the biopharmaceutical industry and university researchers by providing an opportunity to work together to test new technologies and solve big problems. Much like the research being done, these partnerships are in constantly evolving, so this week our Conversations question is:

How can we better utilize public-private partnerships to advance translation of science into new medicines for some of our most challenging diseases, such as neurological disorders?

We look forward to responses from a variety of viewpoints across the health care ecosystem. This forum is designed so that everyone working in health care can share their perspective. We hope you take a moment to review the existing responses and contribute your thoughts.


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context